Incidence of treatment-emergent adverse events was similar between the two groups , with the most common events being respiratory disorders ( @ -LSB- @ % -RSB- of @ patients given placebo vs @ -LSB- @ % -RSB- of @ given benralizumab ) and infections ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .